Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,263 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Copd Clear all
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

NCT03930732
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
51
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

AECOPD and Nutritional Supplementation in COPD

NCT06801964
View directory record Official record
Conditions
Obstructive Pulmonary Disease, Exacerbation Copd
Interventions
Stable isotope infusion, Protein and Fish Oil, Protein and Olive Oil, Carbohydrate and Olive Oil
Other · Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 23, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 23, 2026, 4:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)

NCT00018408
View directory record Official record
Conditions
Chronic Obstructive Lung Disease
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Early Phase 1 Interventional

A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease

NCT01274507
View directory record Official record
Conditions
Asthma, Pulmonary Disease, Chronic Obstructive
Interventions
Medical tests
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
Birmingham, Alabama • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 23, 2026, 4:17 AM EDT
Completed No phase listed Observational

ICS/LABA Adherence and COPD Exacerbation

NCT02446041
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Non-Interventional Study
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 23, 2026, 4:17 AM EDT
Completed No phase listed Observational

Lung HIV Disease in a Large Cohort-Pitt

NCT01326572
View directory record Official record
Conditions
Pulmonary Disease, HIV, Emphysema
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 72 Years · Male only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD

NCT05962645
View directory record Official record
Conditions
COPD, Respiratory Disease, Lower Respiratory Disease, Pulmonary Disease, Healthy
Interventions
Vapendavir
Drug
Lead sponsor
Altesa Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

NCT06040086
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Placebo, Tozorakimab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
57
States / cities
Birmingham, Alabama • Decatur, Alabama • Sheffield, Alabama + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 4:17 AM EDT
Withdrawn No phase listed Observational

Smog Induced Indoor Air Pollution in Homes of Chronic Obstructive Pulmonary Disease Patients.

NCT02775487
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 23, 2026, 4:17 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017

NCT02315131
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD
Interventions
TV46017, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
20 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
St Louis, Missouri • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT03162055
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease COPD
Interventions
Glycopyrronium/Formoterol Fumarate, umeclidinium/vilanterol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 95 Years
Enrollment
1,119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Tempe, Arizona • Escondido, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 23, 2026, 4:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Proteomics of Alveolar Macrophages

NCT00806091
View directory record Official record
Conditions
COPD
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2 Interventional

A Pilot Study to Evaluate a Telepharmacy Intervention to Improve Inhaler Adherence in Veterans With COPD

NCT01270594
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
COPD Inhaler Counseling, Usual Pharmacy Care
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 23, 2026, 4:17 AM EDT
Terminated Not applicable Interventional Results available

Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)

NCT03513068
View directory record Official record
Conditions
COPD
Interventions
Portable Oxygen Concentrator (POC)
Device
Lead sponsor
ResMed
Industry
Eligibility
40 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Denver, Colorado • Chicago, Illinois • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease

NCT01391559
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
arformoterol, salmeterol
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
60 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

NCT01044459
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide 200 µg, Aclidinium Bromide 400 µg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT02105948
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Newport Beach, California • Rochester, Minnesota • Saint Charles, Missouri + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Not applicable Interventional

Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge

NCT04351880
View directory record Official record
Conditions
Heart Failure, Copd, Liver Failure, Diabetes Mellitus, Cancer, End Stage Renal Disease
Interventions
Medically Tailored Meals
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Denver, Colorado • Lafayette, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?

NCT00420160
View directory record Official record
Conditions
Lung Cancer, Heart Disease, COPD
Interventions
Smoking cessation treatment plus moderate intensity exercise, Smoking cessation treatment plus health education
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 4 Interventional Results available

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

NCT04223843
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium + olodaterol, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
21
States / cities
Andalusia, Alabama • Jasper, Alabama • Brandon, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)

NCT02105961
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Riverside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 23, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional

Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

NCT00690885
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Cough
Interventions
interferon-alpha lozenges, placebo lozenges
Drug
Lead sponsor
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Industry
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Results available

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

NCT05326412
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab SAR440340
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Torrance, California • Denver, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 23, 2026, 4:17 AM EDT